sephin-1

Sephin1 (IFB-088) is reportedly a selective inhibitor of GADD34 (PPP1R15A), which is a stress-induced regulatory subunit of protein phosphatase 1 complex that dephosphorylates eIF2α

Icerguastat (IFB-088) is a selective inhibitor of holophosphatase. Sephin1 safely and selectively inhibited a regulatory subunit of protein phosphatase 1 in vivo.

Sephin1 hydrochloride is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A), which prolongs the benefit of eIF2α phosphorylation, thereby protecting cells from proteostatic defects.

IFB-088 acetate, a benzyl guanidine derivative, is used to treat diseases and cancers associated with the PPP1R15A pathway and associated with protein misfolding stress, Examples include tau disease, synaptic riboprotein disease, polyglutamine and polyalanine diseases, leukodystrophy, cystic fibrosis, multiple sclerosis, lysosome storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardiovascular diseases, osteoporosis, neurological trauma, and more.

Icerguastat (Sephin1) Carbonate, a Guanabenz derivative lacking α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). It inhibits the dephosphorylation of eIF2α, thereby prolonging the protective response. Additionally, Icerguastat Carbonate exhibits antiprion activity.